Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: While acute detrimental effects of benzodiazepine (BDZ), and BDZ and related z-substance (BDZR) use on cognition and memory are known, the association of BDZR use and risk of dementia in the elderly is controversially discussed. Previous studies on cohort or claims data mostly show an increased risk for dementia with the use of BDZs or BDZRs. For Germany, analyses on large population-based data sets are missing. OBJECTIVE: To evaluate the association between regular BDZR use and incident any dementia in a large German claims data set. METHODS: Using longitudinal German public health insurance data from 2004 to 2011 we analyzed the association between regular BDZR use (versus no BDZR use) and incident dementia in a case-control design. We examined patient samples aged≥60 years that were free of dementia at baseline. To address potential protopathic bias we introduced a lag time between BDZR prescription and dementia diagnosis. Odds ratios were calculated applying conditional logistic regression, adjusted for potential confounding factors such as comorbidities and polypharmacy. RESULTS: The regular use of BDZRs was associated with a significant increased risk of incident dementia for patients aged≥60 years (adjusted odds ratio [OR] 1.21, 95% confidence interval [CI] 1.13-1.29). The association was slightly stronger for long-acting substances than for short-acting ones. A trend for increased risk for dementia with higher exposure was observed. CONCLUSION: The restricted use of BDZRs may contribute to dementia prevention in the elderly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease
Jo, S., Yarishkin, O., Hwang, Y. J., Chun, Y. E., Park, M., Woo, D. H., Bae, J. Y., Kim, T., Lee, J., Chun, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3639 · Cited by 783 · cited 1×
“[27] detected that astrocytes near A plaques display an increased gamma-aminobutyric acid-secreting activity.”
Cognitive and sedative effects of benzodiazepine use
Buffett-Jerrott, S., & Stewart, S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396654 · Cited by 312 · cited 1×
“and memory are well known [4, 5], the connection between long-term BDZR use and cognitive decline is controversially discussed [6, 7].”
Gray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233 · cited 2×
“The authors of the study mention that their participants might have had lower levels of BDZR exposure compared to other studies [23].”
Marra, E. M., Mazer‐Amirshahi, M., Brooks, G., van den Anker, J., May, L., & Pines, J. M. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13666 · Cited by 47 · cited 1×
“act at gamma-aminobutyric acid A receptors and are widely prescribed for the treatment of sleep disorders and anxiety, particularly in the elderly [1, 2].”
Cited by
The glymphatic system: implications for drugs for central nervous system diseases
Lohela, T. J., Lilius, T. O., & Nedergaard, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00500-9 · Cited by 254
Lucchetta, R. C., da Mata, B. P. M., & Mastroianni, P. D. C. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2170 · Cited by 130
Dyer, A. H., Murphy, C., Lawlor, B., Kennelly, S. P., Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.08.006 · Cited by 39
Landolt, S., Rosemann, T., Blozik, E., Brüngger, B., & Huber, C. A. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s290104 · Cited by 34
Metadata
- Authors
- Gomm, W., von Holt, K., Thomé, F., Broich, K., Maier, W., Weckbecker, K., Fink, A., Doblhammer, G., & Haenisch, B.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-09-06
- Volume
- 54
- Issue
- 2
- Pages
- 801-808
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2508757690
- Cited by
- 55
- References
- 4
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data. https://app.cochat.ai/papers/10.3233/jad-151006
- The paper
- Gomm, W., von Holt, K., Thomé, F., Broich, K., Maier, W., Weckbecker, K., Fink, A., Doblhammer, G., & Haenisch, B. (2016). Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-151006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.